ATC code L01
Abemaciclib
Acalabrutinib
Adagrasib
Afatinib
Aflibercept
Alectinib
Alemtuzumab
Alpelisib
American Society of Health-System Pharmacists
Amivantamab
Anaplastic lymphoma kinase
Anatomical Therapeutic Chemical Classification System
Antineoplastic
Asciminib
AstraZeneca
Atezolizumab
Aumolertinib
Avapritinib
Avelumab
Axatilimab
Axitinib
BRAF (gene)
Baricitinib
Belantamab mafodotin
Bermekimab
Bevacizumab
Binimetinib
Blinatumomab
Bosutinib
Brentuximab vedotin
Brigatinib
Bruton's tyrosine kinase
CAS Registry Number
CD135
CD20
CD30
CD33
CD3 (immunology)
CD52
CDK inhibitor
Cabozantinib
Cancer immunotherapy
Capmatinib
Carboplatin
Catumaxomab
Cediranib
Cemiplimab
Ceritinib
Cetuximab
ChemSpider
Chemical formula
Cisplatin
Cobimetinib
Copanlisib
Cosibelimab
Crizotinib
Dabrafenib
Dacomitinib
DailyMed
Dalpiciclib
Daratumumab
Dasatinib
Denileukin diftitox
Doi (identifier)
Dostarlimab
Duvelisib
EML4
Edrecolomab
Elotuzumab
Elranatamab
Encorafenib
Enfortumab vedotin
Entrectinib
Epcoritamab
Epidermal growth factor receptor
ErbB
Erdafitinib
Erlotinib
Etoposide
Everolimus
Exotoxin
Fedratinib
Fibroblast growth factor receptor
Filgotinib
Food and Drug Administration
Fruquintinib
Fusion protein
Futibatinib
Gefitinib
Gemcitabine
Gemtuzumab ozogamicin
Gilteritinib
Glasdegib
Glofitamab
Hdl (identifier)
Head and neck cancer
Hedgehog signaling pathway
Ibritumomab tiuxetan
Ibrutinib
Icotinib
Idelalisib
Imatinib
Immune checkpoint
Immune system
Immunosuppression
Inavolisib
Infigratinib
Inotuzumab ozogamicin
Interleukin 2
Intravenous therapy
Ipilimumab
Isatuximab
Janus kinase
KRAS
Lapatinib
Molar mass
PMC (identifier)
PMID (identifier)
Public domain
S2CID (identifier)